Abstract A21: Survivin-T34A enhances gemcitabine treatment in pancreatic cancer.

Jonathan R. Aspe; Simone DeShields; Nathan Wall

doi:10.1158/1538-7445.PANCA2012-A21

Abstract A21: Survivin-T34A enhances gemcitabine treatment in pancreatic cancer.

Jonathan R. Aspe, Simone DeShields, Nathan Wall

Loma Linda University

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	American English
Pages (from-to)	A21
Journal	Cancer Research
Volume	72
Issue number	14_Supplement
DOIs	https://doi.org/10.1158/1538-7445.PANCA2012-A21
State	Published - Jul 15 2012

Disciplines

Medicine and Health Sciences
Immunology and Infectious Disease

Access to Document

10.1158/1538-7445.PANCA2012-A21License: Unspecified

OpenUrl availability

Full text

Cite this

@article{70fdcefe7b664064ab011650e2416b95,

title = "Abstract A21: Survivin-T34A enhances gemcitabine treatment in pancreatic cancer.",

author = "Aspe, {Jonathan R.} and Simone DeShields and Nathan Wall",

note = "Pancreatic cancer is the fourth most common cause of cancer fatality in American men and women, with a less than 5% survival rate. Currently, if diagnosed early, surgical resection remains the only viable cure. However, only 20% of pancreatic cancer patients meet these criteria.",

year = "2012",

month = jul,

day = "15",

doi = "10.1158/1538-7445.PANCA2012-A21",

language = "American English",

volume = "72",

pages = "A21",

journal = "Cancer Research",

number = "14_Supplement",

}

TY - JOUR

T1 - Abstract A21: Survivin-T34A enhances gemcitabine treatment in pancreatic cancer.

AU - Aspe, Jonathan R.

AU - DeShields, Simone

AU - Wall, Nathan

N1 - Pancreatic cancer is the fourth most common cause of cancer fatality in American men and women, with a less than 5% survival rate. Currently, if diagnosed early, surgical resection remains the only viable cure. However, only 20% of pancreatic cancer patients meet these criteria.

PY - 2012/7/15

Y1 - 2012/7/15

UR - http://cancerres.aacrjournals.org/content/72/14_Supplement/A21

U2 - 10.1158/1538-7445.PANCA2012-A21

DO - 10.1158/1538-7445.PANCA2012-A21

M3 - Meeting abstract

VL - 72

SP - A21

JO - Cancer Research

JF - Cancer Research

IS - 14_Supplement

ER -

Abstract A21: Survivin-T34A enhances gemcitabine treatment in pancreatic cancer.

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this